// App-Quantinova.ai

O-1 : PanCO: Updated results of an open-label, single-arm pilot study of OncoSil P-32 microparticles in unresectable locally advanced pancreatic adenocarcinoma (LAPC) with gemcitabine + nab-paclitaxel or FOLFIRINOX chemotherapy

Researchers

Presenter

  • P. Ross

Principal Investigators

  • A. Hendlisz

  • T. Ajithkumar

  • C. Iwuji

  • M. Harris

  • D. Croagh

  • M. Aghmesheh

  • A. Nagrial

  • N. Nguyen

  • M. Nikfarjam

  • N. Wilson

  • D. Kenny

  • D. Turner

  • H. Wasan

Medical Centers

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Institut Jules Bordet, Universite libre de Bruxelles, Brussels, Belgium

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • University Hospitals Leicester NHS Trust, Leicester, United Kingdom

  • Monash Health, Melbourne, Australia

  • Southern Medical Day Care Centre, Wollongong, Australia

  • Westmead Hospital, Sydney, Australia

  • Royal Adelaide Hospital, Adelaide, Australia

  • Austin Health, Melbourne, Australia

  • OncoSil Medical Ltd, Sydney, NSW, Australia

  • Adjuvantyx Ltd., Sevenoaks, United Kingdom

  • Hammersmith Hospital NHS Trust, London, United Kingdom

Locations

  • United Kingdom

  • Belgium

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic cancer

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Paclitaxel

  • FOLFIRINOX

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved